Skip to content
Learn More

Resources

Exploring Plant-Based Bioreactors for Developing COVID-19 Therapeutics and Vaccines

October 2, 2020

Biologics company iBio, is focused on developing therapeutics and vaccines using a novel plant-based system. It recently announced a worldwide licensing agreement with Planet Biotec> to develop and manufacture a novel COVID-19 therapeutic calledACE2-Fc.

Technology Networks spoke with iBio’s CEO and Chairman of the Board Thomas Isett, to learn more about the company’s efforts to develop ACE2-Fc as well as two vaccine candidates IBIO-200 and IBIO-201 against SARS-CoV-2. Isett also discusses the key benefits of plant-based manufacturing and highlights additional disease areas that they are working to develop biotherapeutics for.

Learn More

The Advantages of Implementing Plant-Based Vaccines

September 29, 2020

Accelerated development of vaccines is essential to public health and pandemic preparedness, both for the current COVID-19 pandemic and future threats. iBio is developing multiple vaccine platforms — using its, readily scalable FastPharming® plant-based production system with the hope of providing long-term immunity without the safety concerns presented by DNA- and RNA-based vaccines.

Learn More

Applying Rapid Countermeasure Preparedness to Development of a Novel COVID-19 Vaccine

April 24, 2020

The COVID-19 pandemic sweeping across the globe is pushing innovation to the cutting edge throughout the biopharma industry. More rapid development of novel diagnostics, therapeutics, and vaccines is acutely needed to mitigate further spread of the virus and prevent its reoccurrence in the future. iBio is offering its FastPharming Contract Manufacturing Services to vaccine and therapeutic developers to address the need for speeding time-to-clinic for new antigens, antibodies, and other protein biologics using a plant-based expression system. In addition, iBio is developing its own proprietary solutions, notably IBIO-200, a virus-like particle (VLP) vaccine candidate for COVID-19 disease.

Learn More

Fast-Farming Pharma: How plants could speed up vaccine manufacture to tackle the COVID-19 pandemic

April 17, 2020

At the start of April 2020, the global number of confirmed COVID-19 cases was rapidly approaching 1.5 million; the death toll: over 80,000. And these numbers will likely have changed substantially since the publication of this article. A vaccine is urgently needed. Pharma companies are scrambling into action with vaccine candidates and early trials, but drug development will take time. Some companies, however, are taking a different approach by introducing technologies that could help with research or manufacturing. As just one example, iBio is hoping its technology can help accelerate manufacturing and scale up for a potential vaccine.

Learn More
Top